Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Change in Inventory (2016 - 2025)

Phibro Animal Health (PAHC) has 13 years of Change in Inventory data on record, last reported at $47.0 million in Q4 2025.

  • For Q4 2025, Change in Inventory rose 144.49% year-over-year to $47.0 million; the TTM value through Dec 2025 reached $93.1 million, up 555.03%, while the annual FY2025 figure was $44.3 million, 1777.17% up from the prior year.
  • Change in Inventory reached $47.0 million in Q4 2025 per PAHC's latest filing, up from $26.2 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $47.0 million in Q4 2025 and bottomed at -$19.2 million in Q2 2023.
  • Average Change in Inventory over 5 years is $8.8 million, with a median of $5.7 million recorded in 2024.
  • Peak YoY movement for Change in Inventory: surged 1094.67% in 2021, then crashed 220.28% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $12.1 million in 2021, then tumbled by 66.08% to $4.1 million in 2022, then plummeted by 38.1% to $2.5 million in 2023, then soared by 657.06% to $19.2 million in 2024, then surged by 144.49% to $47.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were $47.0 million in Q4 2025, $26.2 million in Q3 2025, and $6.2 million in Q2 2025.